PacBio

Pacific Biosciences impresses with precise long-read DNA analysis; new EpiSign interpretations and a collaboration with TychoBio (data from >10,000 samples) aim to advance AI-supported RNA therapies and stimulate demand. At the same time, Q2 2026 revenue fell 2% to $39.0 million and adjusted loss per share worsened slightly, meaning the operational benefits of the technological advances still need to prove themselves in revenue growth and improved profitability. » Mere på finanzen.net

PacBio reported Q2 revenue of $39 million and saw clinical consumables growth of 67%, but cut its full-year guidance to about $160 million due to delayed rollout of SPRQ‑Nx chemistry and higher compute costs. The company announced a CEO transition to Mark Van Oene, workforce reductions and cost cuts to boost efficiency and realize annual savings of $15–20 million. Large initiatives like the 100,000-sample contract with GeneDx and demand for long-read sequencing support the long-term outlook; the target is positive cash flow in 2028, assuming the next instrument generation launches successfully, compute costs decline and customers migrate to SPRQ‑Nx. » Mere på de.investing.com

PacBio’s board of directors has appointed Mark Van Oene, previously chief operating officer, as president and chief executive officer and added him to the board. He succeeds Christian Henry, who resigned after six years as CEO and will remain with the company as an advisor through the end of 2026. Van Oene, who joined PacBio in 2021, is expected to drive commercialization, product development, the expansion of HiFi sequencing, and the strengthening of the clinical and diagnostic markets. » Mere på de.investing.com

PacBio has begun worldwide shipping of the SPRQ-Nx sequencing chemistry and reusable SMRT cells for the Revio platform, cutting the list price per genome to $345 and allowing enterprise pricing below $300. SPRQ-Nx enables repeated use of SMRT cells, improves methylation detection, and—according to beta tests—delivers higher yield and lower error rates than the previous chemistry. DeepConsensus updates, partly developed with Google’s AlphaEvolve, and new deep-learning models for epigenetics will be available via software upgrades and reagent kits for existing Revio systems; the chemistry is slated to be offered for Vega by the end of 2026. » Mere på de.investing.com

Pacific Biosciences reported revenue of $37.2 million for Q1 2026, missing consensus estimates but beating the non-GAAP loss-per-share expectation. The consumables business reached a record quarter with $21.8 million, while instrument revenue declined 12%. The new SPRQ-Nx chemistry platform is due to launch at the end of May and is expected to significantly lower cost per genome and improve margins. The company raised its full-year guidance to $165–175 million and emphasizes strategic partnerships to strengthen clinical HiFi adoption. » Mere på de.investing.com